The move
As of Sep 25, Apimeds Pharmaceuticals US (APUS) last traded around $6.79, up 114.8% on the session and up 38.0% after hours, on $432.2M of dollar volume, running about 536.0× its normal volume.
Why it is on our radar
Our radar flagged APUS for up 115%, heavy scanner alerts. It fired 43 of our alerts.
What the numbers show
Market cap is about $3.5M; the tradeable float is roughly 1.5M shares (ultra-low float); short interest sits near 1% of float, about 1.0 days to cover; institutions hold around 3.22%.
The latest SEC filing
The most recent SEC filing on record is Material event (8-K) (Sep 23, 2026). Shareholder Rights Change, Charter / Bylaw Change
How we built this
APUS was surfaced by our trending engine, which ranks stocks by real-time move, dollar volume, alert activity, and community chatter. The fundamentals, float, short interest, and filings come straight from our due-diligence data, sourced from SEC EDGAR. Nothing here is a fabricated stat, and nothing here is a recommendation.
Why is APUS moving?
Apimeds Pharmaceuticals US is up on $432.2M of volume and ranks near the top of our trending board for up 115% and heavy scanner alerts. This reflects what our data shows as of Sep 25, not a forecast.
Is APUS heavily shorted?
Short interest in APUS is around 1% of its float, roughly 1.0 days to cover, as of the most recent data we have.
Is this investment advice?
No. This is information and education built from public data, not investment advice, and we are not licensed financial advisors.